Literature DB >> 9657511

Quinine pharmacokinetics: ototoxic and cardiotoxic effects in healthy Caucasian subjects and in patients with falciparum malaria.

F A Claessen1, C J van Boxtel, R M Perenboom, R A Tange, J C Wetsteijn, P A Kager.   

Abstract

OBJECTIVE: To study the pharmacokinetic behaviour of quinine in Caucasians with and without malaria.
METHOD: Quinine-dihydrochloride was administered intravenously as a single dose of 300 mg to 12 healthy subjects and as multiple doses of 600 mg in 4 h every 8 h in 10 patients with falciparum malaria. Plasma quinine concentrations were measured by high-performance liquid chromatography
RESULTS: Quinine pharmacokinetics are time-dependent: the apparent elimination halftime is shorter in the accumulation phase than in the elimination phase; in malaria patients the maximal quinine concentration was reached in half the time calculated on the basis of the elimination phase after the last quinine infusion. Nevertheless a loading dose seemed advisable to reach adequate therapeutic levels quickly. In malaria patients the highest plasma concentrations during or at the end of the infusions were positively correlated with body weight. There was no correlation between body weight and the volume of distribution of quinine as calculated during the elimination phase. Hearing loss was audiometrically documented in 9 healthy subjects at a mean maximal plasma quinine concentration of only 2 mg/l. All malaria patients suffered serious cochlear hearing impairment. The ototoxic effects in both healthy subjects and patients appeared to be reversible. No electrographic changes were noted in the healthy subjects, whereas a clinically insignificant mean lengthening of the corrected QT interval was seen in the malaria patients.
CONCLUSION: Intravenous quinine pharmacokinetics in healthy Caucasians were similar to those reported for Nigerian or Thai subjects. At effective doses quinine causes considerable but reversible cochlear hearing losses in both healthy persons and in patients. Our findings do support the need for a loading dose. The fact that in malaria patients there was no correlation between body weight and quinine VD as calculated during the elimination phase renders questionable the usefulness of dosing quinine according to body weight.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9657511     DOI: 10.1046/j.1365-3156.1998.00252.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  9 in total

1.  High risk of QT interval prolongation and torsades de pointes associated with intravenous quinidine used for treatment of resistant malaria or babesiosis.

Authors:  Heather A Wroblewski; Richard J Kovacs; Joanna R Kingery; Brian R Overholser; James E Tisdale
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

2.  Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.

Authors:  S M D K Ganga Senarathna; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

Review 3.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

4.  Prediction of Antimalarial Drug Clearance in Children: A Comparison of Three Different Interspecies Scaling Methods.

Authors:  Iftekhar Mahmood; Anna Cheng; Edward Brauer; Rita Humeniuk
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.441

5.  Population pharmacokinetic and pharmacodynamic properties of intramuscular quinine in Tanzanian children with severe Falciparum malaria.

Authors:  Ilse C E Hendriksen; Deogratius Maiga; Martha M Lemnge; George Mtove; Samwel Gesase; Hugh Reyburn; Niklas Lindegardh; Nicholas P J Day; Lorenz von Seidlein; Arjen M Dondorp; Joel Tarning; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2012-11-26       Impact factor: 5.191

6.  Severe malaria in children leads to a significant impairment of transitory otoacoustic emissions--a prospective multicenter cohort study.

Authors:  Joachim Schmutzhard; Peter Lackner; Raimund Helbok; Helene Verena Hurth; Fabian Cedric Aregger; Veronika Muigg; Josua Kegele; Sebastian Bunk; Lukas Oberhammer; Natalie Fischer; Leyla Pinggera; Allan Otieno; Bernards Ogutu; Tsiri Agbenyega; Daniel Ansong; Ayola A Adegnika; Saadou Issifou; Patrick Zorowka; Sanjeev Krishna; Benjamin Mordmüller; Erich Schmutzhard; Peter Kremsner
Journal:  BMC Med       Date:  2015-05-28       Impact factor: 8.775

7.  Electrocardiographic study in Ghanaian children with uncomplicated malaria, treated with artesunate-amodiaquine or artemether-lumefantrine.

Authors:  George O Adjei; Collins Oduro-Boatey; Onike P Rodrigues; Lotte C Hoegberg; Michael Alifrangis; Jorgen A Kurtzhals; Bamenla Q Goka
Journal:  Malar J       Date:  2012-12-17       Impact factor: 2.979

8.  Reversible audiometric threshold changes in children with uncomplicated malaria.

Authors:  George O Adjei; Bamenla Q Goka; Emmanuel Kitcher; Onike P Rodrigues; Ebenezer Badoe; Jorgen A L Kurtzhals
Journal:  J Trop Med       Date:  2013-03-07

9.  Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda.

Authors:  Frank Kloprogge; Vincent Jullien; Patrice Piola; Mehul Dhorda; Sulaiman Muwanga; François Nosten; Nicholas P J Day; Nicholas J White; Philippe J Guerin; Joel Tarning
Journal:  J Antimicrob Chemother       Date:  2014-06-25       Impact factor: 5.790

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.